Does Perfadex affect outcomes in clinical lung transplantation?

Area of Science:

• Cardiovascular and Respiratory System
• Transplantation Medicine
• Surgical Innovation

Background:

• Low-potassium dextran (LPD) solutions show promise in experimental lung transplantation models for improving gas exchange.
• Clinical evidence on LPD's efficacy in reducing primary graft dysfunction (PGD) and improving patient outcomes remains controversial.

Purpose of the Study:

• To evaluate the clinical effectiveness of LPD versus modified Euro-Collins (MEC) solution in lung allograft preservation.
• To assess the impact of preservation solution on early graft function and long-term patient survival.

Main Methods:

• A comparative study of 231 lung transplant recipients: 115 receiving LPD-preserved allografts and 116 receiving MEC-preserved allografts.
• Key outcome measures included oxygenation index (OI), PGD grades (ISHLT), extubation times, ICU/hospital length of stay, and survival rates (30-day, 90-day, 1-year).
• Severe PGD was defined as an arterial oxygenation to fraction of inspired oxygen ratio (P/F ratio) <200 within 48 hours post-transplant.

Main Results:

• The LPD group showed a significantly lower incidence of severe PGD (ISHLT Grade III) at 24 hours post-transplant (8% vs. 20%, p=0.03).
• No significant differences were observed in other PGD timepoints, extubation rates, or 30-day, 90-day, and 1-year survival rates between the LPD and MEC groups.
• Bronchiolitis obliterans syndrome (BOS)-free survival at 1 year was also comparable between the two preservation solutions.

Conclusions:

• Lung preservation with LPD does not offer significant advantages over MEC in improving early gas exchange or long-term mortality in clinical lung transplantation.
• The incidence of severe PGD at 24 hours was reduced with LPD, but this did not translate to improved overall outcomes.
• Further investigation into novel lung preservation solutions is crucial for mitigating PGD and enhancing transplant success.